We use cookies for a better user experience. Read our Privacy Policy

I Agree

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Chronic Obstructive Pulmonary Disease [COPD] Treatment Market (Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook 2031

  • The global chronic obstructive pulmonary disease (COPD) treatment market was valued at US$ 19.8 Bn in 2021
  • The global market is projected to grow at a CAGR of 4.4% from 2022 to 2031
  • The global chronic obstructive pulmonary disease (COPD) treatment market is anticipated to reach more than US$ 30.4 Bn by the end of 2031

Analysts’ Viewpoint on Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Scenario

Exposure to tobacco smoke, which includes second­hand or passive exposure, allergens (such as pollen, ragweed, dust mites, or animal dander), irritants in the air (such as chemical fumes, smoke, or strong odors), and extreme weather conditions are the major risk factors driving the global chronic obstructive pulmonary disease treatment market. Other risk factors such as indoor air pollution (such as solid fuel used for heating and cooking), outdoor air pollution, occupational dust and chemicals (such as irritants, vapors, and fumes), and frequent lower respiratory infections during childhood are also propelling the global chronic obstructive pulmonary disease treatment market. Key companies operating in the market are focusing on developing low-cost and effective drugs for the treatment of chronic obstructive pulmonary diseases to increase their global footprint.

Chronic Obstructive Pulmonary Disease Treatment Market

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Introduction

Chronic obstructive pulmonary disease is a group of conditions affecting the lungs that lead to difficulty in breathing. Chronic bronchitis and emphysema are the two major types of chronic obstructive pulmonary diseases. Breathlessness is a key characteristic of COPD. In case of emphysema, the alveoli (tiny air sac) in the lungs is damaged. The walls of the alveoli are stretched, making the lungs bigger and resulting in difficulty in the movement of air. In chronic bronchitis, bronchial airways (breathing tubes) inside the lungs are inflamed. High prevalence of COPD across the globe and rich pipeline of drugs for COPD treatment are likely to drive the global market during the forecast period. Furthermore, increase in geriatric population and unhealthy lifestyle choices among various age groups are projected to propel the chronic obstructive pulmonary disease (COPD) treatment market in the near future.

Request a sample to get extensive insights into the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Rise in Prevalence of COPD Across Globe

Chronic obstructive pulmonary disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management. Tobacco smoking could lead to COPD. The number of adults addicted to smoking has been increasing across the globe. Other risk factors include occupation and indoor air pollution. According to the WHO, the primary cause of COPD is exposure to tobacco smoke (either active smoking or passive smoking). According to the organization, chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, accounting for 3.23 million deaths in 2019. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC). According to a report by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2022, the prevalence and burden of COPD is projected to increase in the near future due to continued exposure to COPD risk factors, rise in incidence of interstitial lung diseases, and aging population across the world. This is anticipated to augment the chronic obstructive pulmonary disease treatment market in the near future.

Increase in Adoption of More Effective Combination Therapy to Drive Global COPD Treatment Market

Combination therapies include LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs. Adoption of combination therapy is increasing, as it is more effective than separate use of bronchodilators and corticosteroids. Increase in the number of patients successfully treated with combination therapy who were not showing signs of recovery with bronchodilators or corticosteroid treatments is expected to fuel the global chronic obstructive pulmonary disease treatment market. Combination therapy is more effective than monotherapy for improving symptoms and quality of life.

Request a custom report on Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Growth in Success Rate of COPD Treatment to Augment Combination Therapy Segment

In terms of drug class, the global COPD treatment market has been classified into combination therapy, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitor, mucokinetics, and others. The combination therapy segment held major share of around 50% of the global market in 2021. It is likely to dominate the global market during the forecast period, owing to the increase in efficacy of combination therapy in COPD treatment. Rise in the success rate of combination therapy in COPD treatment and recent regulatory approvals have augmented the adoption of combination therapy. This is projected to drive the segment during the forecast period.

Surge in Airflow Blockage and Breathing Issues among Smokers Fueling Chronic Bronchitis Segment

In terms of type, the global COPD treatment market has been bifurcated into chronic bronchitis and emphysema. The chronic bronchitis segment accounted for the largest chronic obstructive pulmonary disease treatment market share in 2021. Chronic bronchitis is a group of lung diseases that causes airflow blockage and breathing issues. It is widespread among smokers and rising at a rapid pace.

Rise in Number of COPD Therapeutics Dispensed to Boost Retail Pharmacies Segment

Based on distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is anticipated to account for major share of the global chronic obstructive pulmonary disease treatment market during the forecast period. The segment is expected to grow at a rapid pace during the forecast period, owing to the increase in number of COPD therapeutics dispensed through retail pharmacies and rise in number of retail pharmacies in developing countries.

Regional Outlook of Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

As per chronic obstructive pulmonary disease treatment market analysis, North America accounted for the largest share of around 40% of the global market in 2021. The market in the region is projected to grow at a CAGR of 4.3% from 2022 to 2031. This can be ascribed to the highly structured health care industry and availability of well-defined reimbursement policies from private and public health insurance firms. Furthermore, rise in research & development activities to provide advanced and efficient products, and presence of a large number of players are driving the chronic obstructive pulmonary disease treatment market size in North America.

Europe held the second largest share of the global market in 2021. Well-developed health care infrastructure and increase in incidence of chronic obstructive pulmonary diseases are propelling the COPD treatment market in the region.

The market in Asia Pacific is expected to grow at the fastest CAGR of 4.7% during the forecast period. The region has a relatively untapped chronic obstructive pulmonary disease treatment market compared to developed regions. Therefore, Asia Pacific offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the chronic obstructive pulmonary disease treatment market in the region.

Analysis of Key Players in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

The global chronic obstructive pulmonary disease (COPD) treatment market is consolidated, with the presence of a small number of key players. As per chronic obstructive pulmonary disease treatment market trends, leading players in the market are adopting strategies such as new product development, product launches, product approvals, agreements, partnerships, and mergers. Key players operating in the global chronic obstructive pulmonary disease (COPD) treatment market are Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, and Verona Pharmaceuticals.

Key Developments in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

  • In January 2022, the first patient was enrolled in a phase 4 study comparing Yupelri (revefenacin) to Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD). The safety of these two approved once-daily COPD maintenance treatments would be assessed as well. Yupelri is a bronchodilator, a type of medication that relaxes and widens the lung airways, making breathing easier. It was developed by Theravance Biopharma and Mylan (now part of Viatris). It is available as an inhalable solution via a nebulizer, a small machine that turns liquid into a fine mist.
  • In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for US$ 270 Mn. These products are indicated for the treatment of chronic obstructive pulmonary disease (COPD).
  • In October 2021, Mylan Pharmaceuticals received the FDA approval for its investigational new drug application (ANDA) for Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol), the first approved generic version of AstraZeneca's Symbicort. It is anticipated to be available in dosage strengths of 160 mcg/4.5 mcg and 80 mcg/4.5 mcg for patients with asthma or chronic obstructive pulmonary disease (COPD).
  • In January 2019, CHIESI Farmaceutici S.p.A. entered into an exclusive global license agreement with TiumBio, a clinical-stage private biotech company based in South Korea. TiumBio specializes in research on innovative drugs for rare diseases. The agreement is aimed at developing innovative molecules for usage in the treatment of respiratory diseases.

Each of these players has been profiled in the chronic obstructive pulmonary disease (COPD) treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 19.8 Bn

Market Forecast Value in 2031

More than US$ 30.4 Bn

Growth Rate

4.4%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

Market share analysis by company (2021)

Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials.

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • Combination Therapy
    • Bronchodilators
    • Corticosteroids
    • Phosphodiesterase Type 4 Inhibitor
    • Mucokinetics
    • Others
  • Type
    • Chronic Bronchitis
    • Emphysema
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Companies Profiled

  • Almirall
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Kyowa Hakko Kirin
  • Mylan N.V.
  • Novartis AG
  • Orion Corporation
  • Sanofi
  • Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma
  • Verona Pharmaceuticals

Customization Scope

Available upon request

Pricing

Available upon request

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global chronic obstructive pulmonary disease (COPD) treatment market in 2021?

The global chronic obstructive pulmonary disease (COPD) treatment market was valued at US$ 19.8 Bn in 2021.

How big will be the global chronic obstructive pulmonary disease (COPD) treatment market in 2031?

The global chronic obstructive pulmonary disease (COPD) treatment market is projected to reach more than US$ 30.4 Bn by 2031.

What will be the CAGR of the global chronic obstructive pulmonary disease (COPD) treatment market during the forecast period (2022–2031)?

The global chronic obstructive pulmonary disease (COPD) treatment market is anticipated to grow at a CAGR of 4.4% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Rise in prevalence of chronic obstructive pulmonary disease (COPD) leading to an increase in demand for testing & diagnosis, surge in research & development activities, and growth in awareness about COPD.

What is the market share of the leading segment of the global chronic obstructive pulmonary disease (COPD) treatment market?

The combination therapy segment held around 55% share of the global market in 2021.

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global chronic obstructive pulmonary disease (COPD) treatment market during the forecast period.

Who are the prominent players in the global chronic obstructive pulmonary disease (COPD) treatment market?

F. Hoffmann-La Roche Ltd., AstraZeneca, GlaxoSmithKline plc, Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Boehringer Ingelheim International GmbH, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.)., CHIESI Farmaceutici S.p.A., Orion Corporation, Almirall, Theravance Biopharma, Verona Pharmaceuticals, and Kyowa Hakko Kirin.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlight

2. Assumptions and Research Methodology

3. Executive Summary: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Regulatory Scenario by Region/globally

    5.2. Reimbursement Scenario by Region/globally

    5.3. Pipeline Analysis

    5.4. Technological Advancements

    5.5. Pricing Analysis (Brand pricing, Average Selling Price by Region/Country)

    5.6. Disease Prevalence & Incidence Rate globally with key countries

    5.7. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

    5.8. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2031

        6.3.1. Combination Therapy

            6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            6.3.1.3. Triple therapy

            6.3.1.4. Others

        6.3.2. Bronchodilators

            6.3.2.1. Long Acting Beta Agonist (LABA)

            6.3.2.2. Short Acting Beta Agonist (SABA)

            6.3.2.3. Long Acting Muscarinic Antagonist (LAMA)

        6.3.3. Corticosteroids

        6.3.4. Phosphodiesterase Type 4 Inhibitor

        6.3.5. Mucokinetics

        6.3.6. Others

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Type, 2017–2031

        7.3.1. Chronic Bronchitis

        7.3.2. Emphysema

    7.4. Market Attractiveness Analysis, by Type

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2031

        10.2.1. Combination Therapy

            10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            10.2.1.3. Triple therapy

            10.2.1.4. Others

        10.2.2. Bronchodilators

            10.2.2.1. Long Acting Beta Agonist (LABA)

            10.2.2.2. Short Acting Beta Agonist (SABA)

            10.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

        10.2.3. Corticosteroids

        10.2.4. Phosphodiesterase Type 4 Inhibitor

        10.2.5. Mucokinetics

        10.2.6. Others

    10.3. Market Value Forecast, by Type, 2017–2031

        10.3.1. Chronic Bronchitis

        10.3.2. Emphysema

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Type

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2031

        11.2.1. Combination Therapy

            11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            11.2.1.3. Triple therapy

            11.2.1.4. Others

        11.2.2. Bronchodilators

            11.2.2.1. Long Acting Beta Agonist (LABA)

            11.2.2.2. Short Acting Beta Agonist (SABA)

            11.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

        11.2.3. Corticosteroids

        11.2.4. Phosphodiesterase Type 4 Inhibitor

        11.2.5. Mucokinetics

        11.2.6. Others

    11.3. Market Value Forecast, by Type, 2017–2031

        11.3.1. Chronic Bronchitis

        11.3.2. Emphysema

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Type

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2031

        12.2.1. Combination Therapy

            12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            12.2.1.3. Triple therapy

            12.2.1.4. Others

        12.2.2. Bronchodilators

            12.2.2.1. Long Acting Beta Agonist (LABA)

            12.2.2.2. Short Acting Beta Agonist (SABA)

            12.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

        12.2.3. Corticosteroids

        12.2.4. Phosphodiesterase Type 4 Inhibitor

        12.2.5. Mucokinetics

        12.2.6. Others

    12.3. Market Value Forecast, by Type, 2017–2031

        12.3.1. Chronic Bronchitis

        12.3.2. Emphysema

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Type

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2031

        13.2.1. Combination Therapy

            13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            13.2.1.3. Triple therapy

            13.2.1.4. Others

        13.2.2. Bronchodilators

            13.2.2.1. Long Acting Beta Agonist (LABA)

            13.2.2.2. Short Acting Beta Agonist (SABA)

            13.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

        13.2.3. Corticosteroids

        13.2.4. Phosphodiesterase Type 4 Inhibitor

        13.2.5. Mucokinetics

        13.2.6. Others

    13.3. Market Value Forecast, by Type, 2017–2031

        13.3.1. Chronic Bronchitis

        13.3.2. Emphysema

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Type

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2031

        14.2.1. Combination Therapy

            14.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)

            14.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

            14.2.1.3. Triple therapy

            14.2.1.4. Others

        14.2.2. Bronchodilators

            14.2.2.1. Long Acting Beta Agonist (LABA)

            14.2.2.2. Short Acting Beta Agonist (SABA)

            14.2.2.3. Long Acting Muscarinic Antagonist (LAMA)

        14.2.3. Corticosteroids

        14.2.4. Phosphodiesterase Type 4 Inhibitor

        14.2.5. Mucokinetics

        14.2.6. Others

    14.3. Market Value Forecast, by Type, 2017–2031

        14.3.1. Chronic Bronchitis

        14.3.2. Emphysema

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Type

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2021

    15.3. Company Profiles

        15.3.1. F. Hoffmann-La Roche Ltd.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Product Portfolio

            15.3.1.3. Financial Overview

            15.3.1.4. SWOT Analysis

            15.3.1.5. Strategic Overview

        15.3.2. AstraZeneca

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Product Portfolio

            15.3.2.3. Financial Overview

            15.3.2.4. SWOT Analysis

            15.3.2.5. Strategic Overview

        15.3.3. GlaxoSmithKline plc

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Product Portfolio

            15.3.3.3. Financial Overview

            15.3.3.4. SWOT Analysis

            15.3.3.5. Strategic Overview

        15.3.4. Sanofi

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Product Portfolio

            15.3.4.3. Financial Overview

            15.3.4.4. SWOT Analysis

            15.3.4.5. Strategic Overview

        15.3.5. Novartis AG

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Product Portfolio

            15.3.5.3. Financial Overview

            15.3.5.4. SWOT Analysis

            15.3.5.5. Strategic Overview

        15.3.6. Teva Pharmaceutical Industries Ltd.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Product Portfolio

            15.3.6.3. Financial Overview

            15.3.6.4. SWOT Analysis

            15.3.6.5. Strategic Overview

        15.3.7. Mylan N.V.

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Product Portfolio

            15.3.7.3. Financial Overview

            15.3.7.4. SWOT Analysis

            15.3.7.5. Strategic Overview

        15.3.8. Boehringer Ingelheim International GmbH

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Product Portfolio

            15.3.8.3. Financial Overview

            15.3.8.4. SWOT Analysis

            15.3.8.5. Strategic Overview

        15.3.9. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Product Portfolio

            15.3.9.3. Financial Overview

            15.3.9.4. SWOT Analysis

            15.3.9.5. Strategic Overview

        15.3.10. CHIESI Farmaceutici S.p.A.

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Product Portfolio

            15.3.10.3. Financial Overview

            15.3.10.4. SWOT Analysis

            15.3.10.5. Strategic Overview

        15.3.11. Orion Corporation

            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.11.2. Product Portfolio

            15.3.11.3. Financial Overview

            15.3.11.4. SWOT Analysis

            15.3.11.5. Strategic Overview

        15.3.12. Almirall

            15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.12.2. Product Portfolio

            15.3.12.3. Financial Overview

            15.3.12.4. SWOT Analysis

            15.3.12.5. Strategic Overview

        15.3.13. Theravance Biopharma

            15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.13.2. Product Portfolio

            15.3.13.3. Financial Overview

            15.3.13.4. SWOT Analysis

            15.3.13.5. Strategic Overview

        15.3.14. Verona Pharmaceuticals

            15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.14.2. Product Portfolio

            15.3.14.3. Financial Overview

            15.3.14.4. SWOT Analysis

            15.3.14.5. Strategic Overview

        15.3.15. Kyowa Hakko Kirin

            15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.15.2. Product Portfolio

            15.3.15.3. Financial Overview

            15.3.15.4. SWOT Analysis

            15.3.15.5. Strategic Overview

List of Tables

Table 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 02: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by 2017‒2031, by Combination Therapy

Table 03: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by 2017‒2031, by Bronchodilators

Table 04: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 08: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 09: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

Table 10: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

Table 11: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 12: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 15: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

Table 16: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

Table 17: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 18: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 19: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 21: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

Table 22: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

Table 23: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 24: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 25: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 26: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 27: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

Table 28: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

Table 29: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 30: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 31: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 32: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031

Table 33: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017‒2031

Table 34: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017‒2031

Table 35: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 36: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share, by Drug Class, 2021

Figure 03: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share, by Type, 2021

Figure 04: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share, by Distribution Channel 2021

Figure 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 07: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Combination Therapy, 2017‒2031

Figure 08: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Bronchodilators, 2017‒2031

Figure 09: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Corticosteroids 2017‒2031

Figure 10: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Phosphodiesterase Type 4 Inhibitor, 2017‒2031

Figure 11: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Mucokinetics 2017‒2031

Figure 12: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Others, 2017‒2031

Figure 13: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

Figure 14: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 15: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Chronic Bronchitis, 2017–2031

Figure 16: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Emphysema, 2017–2031

Figure 17: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 18: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 19: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031

Figure 20: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

Figure 21: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031

Figure 22: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region, 2021 and 2031

Figure 23: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region, 2022–2031

Figure 24: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 25: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country, 2021 and 2031

Figure 26: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country, 2022–2031 

Figure 27: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 28: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 29: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

Figure 30: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 31: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 32: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 33: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 34: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 35: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 36: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 37: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 38: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

Figure 39: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 40: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 41: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 42: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 43: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 44: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 45: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 46: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 47: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

Figure 48: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 49: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 50: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 51: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 52: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 53: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031

Figure 54: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 55: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 56: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

Figure 57: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 58: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 59: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 60: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 61: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 62: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031

Figure 63: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

Figure 64: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 65: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031

Figure 66: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022–2031

Figure 67: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 68: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 69: Company Share Analysis, 2021

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

126

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved